Squarepoint’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $52.2M | Buy |
695,276
+258,997
| +59% | +$20.4M | 0.06% | 331 |
|
|
2025
Q4 | $34.5M | Buy |
436,279
+52,487
| +14% | +$3.95M | 0.04% | 534 |
|
|
2025
Q3 | $25.1M | Buy |
383,792
+249,397
| +186% | +$12.2M | 0.03% | 639 |
|
|
2025
Q2 | $5.31M | Sell |
134,395
-170,978
| -56% | -$5.6M | 0.01% | 1418 |
|
|
2025
Q1 | $9.21M | Buy |
305,373
+138,905
| +83% | +$4.55M | 0.01% | 1067 |
|
|
2024
Q4 | $5.82M | Buy |
166,468
+39,127
| +31% | +$1.46M | 0.01% | 1514 |
|
|
2024
Q3 | $5.1M | Sell |
127,341
-309,477
| -71% | -$14.4M | 0.01% | 1408 |
|
|
2024
Q2 | $20.8M | Sell |
436,818
-308,355
| -41% | -$12.6M | 0.03% | 564 |
|
|
2024
Q1 | $32.3M | Buy |
745,173
+685,969
| +1,159% | +$32.7M | 0.06% | 411 |
|
|
2023
Q4 | $3M | Sell |
59,204
-80,316
| -58% | -$3.85M | 0.01% | 1732 |
|
|
2023
Q3 | $6.33M | Buy |
139,520
+71,711
| +106% | +$2.96M | 0.02% | 1035 |
|
|
2023
Q2 | $2.78M | Sell |
67,809
-45,591
| -40% | -$1.75M | 0.01% | 1450 |
|
|
2023
Q1 | $4.05M | Sell |
113,400
-67,607
| -37% | -$2.54M | 0.02% | 991 |
|
|
2022
Q4 | $6.84M | Buy |
181,007
+88,953
| +97% | +$3.74M | 0.03% | 676 |
|
|
2022
Q3 | $4.07M | Sell |
92,054
-37,886
| -29% | -$1.6M | 0.02% | 884 |
|
|
2022
Q2 | $4.81M | Buy |
129,940
+111,046
| +588% | +$4.19M | 0.03% | 695 |
|
|
2022
Q1 | $700K | Sell |
18,894
-42,446
| -69% | -$1.39M | ﹤0.01% | 1807 |
|
|
2021
Q4 | $1.87M | Sell |
61,340
-108,525
| -64% | -$3.42M | ﹤0.01% | 1304 |
|
|
2021
Q3 | $5.7M | Buy |
169,865
+122,120
| +256% | +$4.6M | 0.02% | 715 |
|
|
2021
Q2 | $1.91M | Buy |
47,745
+28,158
| +144% | +$1.1M | 0.01% | 1212 |
|
|
2021
Q1 | $881K | Sell |
19,587
-83,903
| -81% | -$4.68M | 0.01% | 1612 |
|
|
2020
Q4 | $5.85M | Buy |
103,490
+34,896
| +51% | +$1.74M | 0.04% | 424 |
|
|
2020
Q3 | $3.25M | Buy |
68,594
+57,739
| +532% | +$3.21M | 0.04% | 482 |
|
|
2020
Q2 | $640K | Sell |
10,855
-137,289
| -93% | -$7.64M | 0.01% | 1168 |
|
|
2020
Q1 | $7M | Buy |
148,144
+30,272
| +26% | +$1.69M | 0.18% | 127 |
|
|
2019
Q4 | $7.12M | Sell |
117,872
-32,459
| -22% | -$1.93M | 0.04% | 390 |
|
|
2019
Q3 | $9.01M | Sell |
150,331
-11,587
| -7% | -$755K | 0.08% | 309 |
|
|
2019
Q2 | $10.4M | Buy |
161,918
+41,738
| +35% | +$2.95M | 0.1% | 246 |
|
|
2019
Q1 | $9.76M | Buy |
120,180
+109,460
| +1,021% | +$7.06M | 0.1% | 238 |
|
|
2018
Q4 | $580K | Buy |
+10,720
| New | +$547K | 0.01% | 1175 |
|
|
2018
Q1 | – | Sell |
-98,617
| Closed | -$4.96M | – | 1908 |
|
|
2017
Q4 | $4.96M | Buy |
98,617
+81,655
| +481% | +$4.48M | 0.09% | 275 |
|
|
2017
Q3 | $860K | Buy |
16,962
+12,634
| +292% | +$662K | 0.02% | 788 |
|
|
2017
Q2 | $220K | Sell |
4,328
-672
| -13% | -$31.3K | ﹤0.01% | 1273 |
|
|
2017
Q1 | $201K | Buy |
+5,000
| New | +$225K | 0.01% | 1286 |
|
|
2016
Q4 | – | Sell |
-9,200
| Closed | -$337K | – | 1837 |
|
|
2016
Q3 | $337K | Buy |
+9,200
| New | +$288K | 0.02% | 692 |
|
|
2016
Q2 | – | Sell |
-12,700
| Closed | -$514K | – | 1220 |
|
|
2016
Q1 | $514K | Buy |
12,700
+3,100
| +32% | +$126K | 0.04% | 614 |
|
|
2015
Q4 | $595K | Buy |
+9,600
| New | +$518K | 0.07% | 450 |
|
|
2015
Q3 | – | Sell |
-23,000
| Closed | -$1.32M | – | 498 |
|
|
2015
Q2 | $1.32M | Buy |
+23,000
| New | +$1.46M | 0.43% | 57 |
|
Other funds holding IONS
VPM
VCM
Squarepoint's IONS Position: Q1 2026 in Review
Squarepoint increased its Ionis Pharmaceuticals (IONS) stake by 59% in Q1 2026, buying an estimated $20.4M and bringing the position to 695,276 shares worth $52.2M. The position accounts for 0.06% of the portfolio, ranked #331.
Squarepoint first reported a position in IONS in Q2 2015 and has held it in 38 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Squarepoint held 695,276 shares of Ionis Pharmaceuticals worth $52.2M as of Q1 2026.
- Squarepoint bought 258,997 Ionis Pharmaceuticals shares in Q1 2026, an estimated $20.4M.
- Ionis Pharmaceuticals made up 0.06% of Squarepoint's portfolio in Q1 2026, its #331 holding.
- Squarepoint first reported a position in Ionis Pharmaceuticals in Q2 2015 and has held it in 38 quarters since.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.